Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 60

Bupivacaine versus ropivacaine for bleeding control and pain in lower wisdom tooth removal

Official title: Comparative Experimental Study Between Bupivacaine and Ropivacaine Regarding Efficacy in Third Molar Removal Surgery Under General Anesthesia

Run by Federal University of Rio Grande do Sul · NCT07108465 · Data updated 2026-11-12

This project will test whether bupivacaine or ropivacaine gives better bleeding control, steadier vital signs, and less pain after lower wisdom tooth removal under general anesthesia in adults.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment15 (estimated)
SponsorFederal University of Rio Grande do Sul
Academic / other
Locations1 site (Porto Alegre, Rio Grande do Sul)
StatusRecruiting
StartedJuly 1, 2025
Main results expectedSeptember 30, 2025
Study endsDecember 31, 2026
Registry record updatedMay 1, 2026
Trial IDNCT07108465 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–60 with ASA physical status I or II and impacted or semi-impacted lower third molars positioned similarly on both sides (per Pell and Gregory) are ideal candidates.

Probably not a fit

Patients who are eligible for local anesthesia, who require additional procedures in the same session, who are ASA III or higher, or who fall outside the 18–60 age range may not receive benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early phase 1, interventional split-mouth comparison gives each participant one side treated with bupivacaine 0.5% and the other with ropivacaine 0.75% during lower third molar extraction under general anesthesia. Investigators will record intraoperative hemostasis and changes in vital signs and ask participants to complete a Visual Analog Scale for postoperative pain. The design enrolls healthy adults (ASA I–II) with similarly positioned impacted or semi-impacted lower third molars on both sides. The study is conducted at Hospital de Clínicas de Porto Alegre with a single surgical session and postoperative follow-up.

Why it matters

Potential benefit: If successful, the trial could identify the anesthetic that produces less postoperative pain and better bleeding control with fewer vital sign disturbances, improving recovery after lower wisdom tooth extraction.

How similar studies have gone: Previous comparisons of bupivacaine and ropivacaine in regional and dental anesthesia generally show comparable pain control with ropivacaine having a more favorable cardiotoxicity profile, but split-mouth comparisons under general anesthesia for third molar removal are less common.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged 18 to 60
* Patients ASA Physical Status Classification I and II
* Patients with impacted or semi-impacted lower third molars with similar positioning on both sides according to the Pell and Gregory classification

Exclusion Criteria:

* Patients who can have surgery under local anesthesia
* Patients where more procedures are required in the same surgical session

Where it's running

  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul, Brazil
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.